Urological Oncology Department II

The hospital reports increasing and younger-onset kidney and prostate cancer and relatively stable bladder cancer incidence. It describes Urologic Oncology Department 2 at the First Hospital of Dalian Medical University as nationally advanced in minimally invasive treatment of urinary and male reproductive tumors.

The department was an early Chinese adopter of kidney-preserving tumor excision and related basic research, with findings contributing to recommendations for nephron-sparing surgery. It has urological diagnostic and surgical equipment, including what the hospital calls the first fourth-generation robot-assisted laparoscopy system in Northeast China. It performs surgery for most urological conditions, including complex adrenal tumor excision, complex nephron-sparing surgery, renal pelvis and ureteral tumors, radical cystectomy with bowel-based bladder substitution, radical prostatectomy with preservation of sexual function, total pelvic organ excision for advanced bladder cancer and percutaneous nephroscopy for kidney stones. The hospital reports improved recovery, survival and quality of life and reduced recurrence, mortality and severe complications in its urological patients.

The department has two master’s supervisors and one doctoral supervisor. Its subspecialties include oncology, stones, andrology and prostate disease. The hospital describes its kidney tumor research as leading in the province and advanced nationally. Techniques include laparoscopic and open nephron-sparing surgery and radical nephrectomy for cancer; laparoscopic radical cystectomy and radical prostatectomy; endoscopic adrenal tumor excision; transurethral minimally invasive procedures for bladder tumors and prostate cancer; percutaneous nephroscopy; ureteroscopy; and diagnosis and treatment of male reproductive conditions.